The stock price of Leap Therapeutics Inc (NASDAQ: LPTX) has jumped by 7.95 compared to previous close of 0.39. Despite this, the company has seen a gain of 5.85% in its stock price over the last five trading days. prnewswire.com reported 2025-04-25 that FL-501 fully restored body composition and reversed key indicators of cachexia in preclinical models Findings confirm GDF-15’s role in cachexia and support advancing FL-501 into the clinic CAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ — Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present preclinical data of FL-501 in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois.
Is It Worth Investing in Leap Therapeutics Inc (NASDAQ: LPTX) Right Now?
The 36-month beta value for LPTX is at -0.16. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for LPTX is 30.61M, and currently, shorts hold a 11.31% of that float. The average trading volume for LPTX on May 01, 2025 was 2.29M shares.
LPTX’s Market Performance
LPTX’s stock has seen a 5.85% increase for the week, with a 37.04% rise in the past month and a -26.85% fall in the past quarter. The volatility ratio for the week is 6.59%, and the volatility levels for the past 30 days are at 13.86% for Leap Therapeutics Inc. The simple moving average for the past 20 days is 19.40% for LPTX’s stock, with a -79.24% simple moving average for the past 200 days.
Analysts’ Opinion of LPTX
Many brokerage firms have already submitted their reports for LPTX stocks, with Robert W. Baird repeating the rating for LPTX by listing it as a “Neutral.” The predicted price for LPTX in the upcoming period, according to Robert W. Baird is $1.25 based on the research report published on January 29, 2025 of the current year 2025.
Rodman & Renshaw gave a rating of “Buy” to LPTX, setting the target price at $8 in the report published on June 28th of the previous year.
LPTX Trading at 6.70% from the 50-Day Moving Average
After a stumble in the market that brought LPTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.27% of loss for the given period.
Volatility was left at 13.86%, however, over the last 30 days, the volatility rate increased by 6.59%, as shares surge +43.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.31% lower at present.
During the last 5 trading sessions, LPTX rose by +5.85%, which changed the moving average for the period of 200-days by -82.21% in comparison to the 20-day moving average, which settled at $0.3504. In addition, Leap Therapeutics Inc saw -85.46% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for LPTX
The total capital return value is set at -2.0. Equity return is now at value -141.94, with -110.79 for asset returns.
Based on Leap Therapeutics Inc (LPTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -226.69.
Currently, EBITDA for the company is -70.06 million with net debt to EBITDA at 0.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.41.
Conclusion
In conclusion, Leap Therapeutics Inc (LPTX) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
